ロード中...
Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
The BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib. Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dim...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7456617/ https://ncbi.nlm.nih.gov/pubmed/32922659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27681 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|